Vanguards of Healthcare by Bloomberg Intelligence

Senseonics CEO discusses Eversense CGM technology, market expansion, and path to profitability

44 min Listen to the original Episode page
Diabetes TechnologyCGM MarketMedical DevicesHealthcare PolicyBiotechMedTechClinical TrialsReimbursement

Summary

Senseonics CEO Tim Goodnow outlines the company's fluorescent-based Eversense CGM, highlighting its 365-day implant duration and 8% MARD accuracy. He discusses partnerships with Medtronic and Beta Bionics, noting strong sales performance and integration capabilities. Goodnow forecasts a $15 billion global CGM market, citing CMS coverage expansion to non-insulin-dependent Type 2 diabetes as a key growth driver. The company reports 90% patient switch rates from competitors and utilizes a dual-channel sales strategy involving direct-to-consumer marketing and a nurse insertion network. Goodnow projects break-even within 18 months following the launch of the 'Freedom' product, which integrates battery and Bluetooth directly into the sensor.

Episode sections

  1. 0:07 – 1:22

    Sponsor Read: Advertisement for Samsung Galaxy S26 Ultra on Bell network.

    Advertisement for Samsung Galaxy S26 Ultra on Bell network.

  2. 1:22 – 4:59

    Career Overview and Background

    CEO Tim Goodnow discusses his chemistry background, PhD in electrochemistry, and previous roles at Baxter Healthcare, Theraseps, and Abbott before joining Senseonics.

  3. 4:59 – 11:40

    Eversense Technology and Design

    Goodnow explains the Eversense sensor's size (4mm x 15mm), its fluorescent measurement technology using anthracene in hydrogels, and the challenge of managing the foreign body response to achieve a 365-day lifespan.

  4. 11:40 – 14:19

    Accuracy and Clinical Performance

    The speaker highlights an 8% MARD, FDA ICGM designation for pump interoperability, and superior accuracy at low glucose levels due to the light-based measurement's dynamic range.

  5. 14:19 – 17:04

    Pump Integrations

    Senseonics partners with Medtronic and is launching with Beta Bionics; Goodnow notes that derivative products from existing partners like Beta Bionics may have shorter integration timelines.

  6. 17:04 – 25:32

    Gemini and Freedom Product Roadmap

    Gemini adds an internal battery to eliminate the external transmitter, while Freedom adds Bluetooth directly to the sensor; both are in development with clinical trials underway or planned.

  7. 25:32 – 27:37

    Market Outlook and CMS Coverage

    Goodnow forecasts the CGM market at $15 billion globally and anticipates growth from CMS coverage expansion to non-insulin-dependent Type 2 diabetes patients, balanced against competitive bidding pressures.

  8. 27:37 – 29:26

    Patient Adoption and Awareness

    Speaker_2 states that 90% of Senseonics patients switch from existing CGMs, driven by the desire for a once-yearly implant. The company is increasing Direct-to-Consumer (DTC) marketing via social media and influencers, which often leads patients to request the product from their doctors.

  9. 29:26 – 35:15

    Sales Channels and Provider Education

    The company utilizes a dual-channel strategy: DTC marketing creates patient demand, while a sales force educates endocrinologists and diabetologists. Approximately 60% of insertions are performed by doctors in large clinics, while the remaining 40% are handled by a contracted nurse network called Eon Care.

  10. 35:15 – 38:05

    Manufacturing and Gross Margins

    Senseonics employs a three-part manufacturing process involving microelectronics, polymer chemistry (partnered with Contamac), and sterilization. Despite low volume, gross margins are in the 60s because the cost of a single sensor is amortized over 365 days, unlike daily disposable CGMs.

  11. 38:05 – 41:07

    Path to Break-Even and 'Freedom' Product

    CEO Tim Goodnow projects the company will reach break-even within 18 months with the launch of the 'Freedom' product, which integrates battery and Bluetooth directly into the sensor, eliminating the external transmitter. The company has sufficient cash to fund this development.

  12. 41:07 – 44:09

    Algorithm Performance and Future Innovation

    The company partners with Sugar.iQ to improve glucose control, claiming a 76% time-in-range for users. Goodnow expresses confidence in extending sensor life beyond 365 days through future battery and algorithm innovations, while hoping for immune protection therapies for Type 1 diabetes within the next decade.

Assets discussed

AssetKindStanceContext
ABBOTT LABORATORIESABTequityneutralThe other thing that you just mentioned. is that it's uh an ICGM like Abbott, like DEXCOM.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

Tim Goodnow has been with Senseonics for over ten years.

Unidentified speaker (speaker_3) ·1:22

How to verify: Check Senseonics executive biographies on the company investor relations page or SEC filings (e.g., proxy statements) for employment start dates. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

Goodnow holds a PhD in electrochemistry from his time at Baxter Healthcare.

Unidentified speaker (speaker_3) ·2:21

How to verify: Verify via Senseonics official press releases, executive bios, or academic publications listing his affiliation and degree. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Theraseps was acquired by Abbott.

Unidentified speaker (speaker_3) ·2:47

How to verify: Search SEC filings (Schedule 14C or 8-K) from Abbott Laboratories or Theraseps regarding the acquisition transaction. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

The Eversense sensor dimensions are approximately 4mm by 15mm.

Unidentified speaker (UNKNOWN) ·5:15

How to verify: Check the FDA 510(k) clearance summary for the Eversense CGM system or the product user manual/spec sheet on the Senseonics website. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Senseonics has approximately 120 issued US patents.

Unidentified speaker (speaker_2) ·9:55

How to verify: Search the USPTO patent database for assignee 'Senseonics' and filter for 'issued' patents. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Eversense holds ICGM (integrated Continuous Glucose Monitor) designation from the FDA.

Unidentified speaker (UNKNOWN) ·12:31

How to verify: Search FDA device databases for 'ICGM' designation or check the FDA's list of cleared/integrated CGMs for interoperability with insulin pumps. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Senseonics is launching a partnership with Beta Bionics.

Unidentified speaker (speaker_3) ·14:53

How to verify: Verify via press releases from Senseonics or Beta Bionics regarding the collaboration. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

The global CGM market is forecast to be about $15 billion.

Unidentified speaker (UNKNOWN) ·25:51

How to verify: Compare this figure against market research reports from firms like Evaluate MedTech, Grand View Research, or company revenue disclosures in SEC filings (e.g., Dexcom, Abbott, Medtronic) for the relevant period. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

90% of Senseonics patients are switching from an existing CGM, while 10% are brand new users.

Unidentified speaker (speaker_2) ·27:37

How to verify: Check Senseonics investor presentations or earnings call transcripts from 2026-2026 for patient acquisition mix data. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

60% of insertions are performed by doctors/medical professionals; 40% are performed by the Eon Care nurse network.

Unidentified speaker (speaker_2) ·31:26

How to verify: Review Senseonics operational updates or investor day materials detailing procedure volume by provider type. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

The Eon Care network has approximately 100 nurses, with a target of 120 by the end of the year.

Unidentified speaker (UNKNOWN) ·32:10

How to verify: Verify against Senseonics corporate communications or press releases from late 2026 regarding Eon Care expansion. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Gross margins are in the 60s (60%+).

Unidentified speaker (speaker_2) ·36:50

How to verify: Check Senseonics audited financial statements (Form 10-K or 10-Q) for gross margin percentage. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

The company will reach break-even within 18 months with the launch of the 'Freedom' product.

Unidentified speaker (speaker_2) ·38:09

How to verify: Compare the stated 18-month timeline against Senseonics' product launch announcements and subsequent quarterly financial results. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Sugar.iQ partnership results in a 76% time-in-range for Eversense users.

Unidentified speaker (speaker_2) ·41:37

How to verify: Search for published clinical studies or white papers from Sugar.iQ and Senseonics validating the 76% time-in-range metric. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Contamac is a supplier of hydrogels for contact lenses and interocular lenses.

Unidentified speaker (speaker_2) ·37:34

How to verify: Check Contamac corporate website or industry reports on hydrogel suppliers for ophthalmic applications. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Senseonics has worked with CMS to establish CPT codes for 90-day, 180-day, and 365-day products.

Unidentified speaker (UNKNOWN) ·34:49

How to verify: Search CMS CPT code database for codes related to continuous glucose monitoring implantable devices and their effective dates. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

Dexcom has been a big sponsor of clinical studies for CMS reimbursement.

Unidentified speaker (speaker_2) ·34:19

How to verify: Review clinical trial registries (e.g., ClinicalTrials.gov) for sponsors of CGM reimbursement studies. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Verify Senseonics' latest 10-K or 10-Q filings for gross margin trends, cash burn rate, and R&D expenses related to Freedom and Gemini development.
  • Check FDA databases for the status of Senseonics' ICGM designation and any recent PMA approvals or 510(k) clearances for new products.
  • Review CMS Medicare Fee Schedule updates to confirm current CPT codes and coverage policies for CGMs, specifically regarding non-insulin-dependent Type 2 diabetes.
  • Analyze competitor filings (e.g., Dexcom, Abbott, Medtronic) for their latest CGM launch timelines, pricing strategies, and market share data.
  • Examine clinical trial registries (ClinicalTrials.gov) for Senseonics' ongoing studies on sensor longevity beyond 365 days and algorithm performance with Sugar.iQ.
  • Assess the competitive landscape for once-yearly implants, including any emerging patents or technologies from other medtech companies addressing foreign body response.
  • Verify the financial health and contractual terms of Eon Care, the nurse insertion network, to understand cost structures and scalability of the direct-to-consumer channel.
  • Review recent analyst reports and earnings call transcripts for Senseonics to compare management's break-even projections with Wall Street consensus estimates.
Full transcriptexpand

0:01Unidentified speaker (UNKNOWN): Oh,

0:01Unidentified speaker (speaker_0): group shot.

0:02Unidentified speaker (speaker_1): I'll take it.

0:03Unidentified speaker (speaker_0): No, we're good. There's one in every group:

0:06Unidentified speaker (speaker_1): the

0:06Unidentified speaker (speaker_0): notographer.

0:07Unidentified speaker (speaker_1): Best

0:07Unidentified speaker (speaker_0): intentions,

0:08Unidentified speaker (speaker_1): worst shots. But there's hope. The Samsung Galaxy S26 Ultra on Bell. Super steady videos and perfectly framed shots with my FamCam. And nitography for stellar picks even in low light.

0:19Unidentified speaker (speaker_2): I want that. Yep,

0:20Unidentified speaker (speaker_1): postworthy with just a to click. All on Bell, Canada's fastest 5G plus network. Visit a bell store or bell.ca slash Samsung for details. Bell. Connection is everything.

0:50Unidentified speaker (speaker_3): Welcome to another episode of the Vanguards of Healthcare series. My name is Matt Henrickson, the medical technology analyst at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP. We are pleased to have with us today Tim Goodnow, CEO of Sensionics, a medical device company that is developing implantable continuous glucose monitors, or CGMs for short, for patients with diabetes. You can dive deeper into the company and its financials by typing in S E N S Equity Go on your Bloomberg terminal. Tim, thank you for joining us. Great. Thanks to be here,

1:21Unidentified speaker (speaker_2): Matt. Appreciate the time.

1:22Unidentified speaker (speaker_3): Yeah. Uh why don't we just start with an overview of your career path that led you to uh Sensionics? I know you've been there now for over ten years now. Um, and kind of, you know, how has the company evolved over that time?

1:37Unidentified speaker (speaker_2): Sure.

1:38Unidentified speaker (UNKNOWN): So

1:38Unidentified speaker (speaker_2): uh Sensionics is a an incredible technology story, and I am absolutely a technologist myself. I came up actually through the uh medical device. I've always been in healthcare my entire career. Very early on, right out of college with a chemistry degree. I went to work for a uh diagnostics company. So did immunodiagnostics and that led to my entire career and now come up to the organization and ultimately got an opportunity. as uh CEO, but through the uh the technology channel, which is a little bit atypical.

2:09Unidentified speaker (speaker_3): Mm-hmm. Yeah. And so so you were at Censionics even before you you started as a CEO and you worked your way up with that platform?

2:16Unidentified speaker (UNKNOWN): No,

2:16Unidentified speaker (speaker_2): I actually

2:16Unidentified speaker (UNKNOWN): was

2:17Unidentified speaker (speaker_2): recruited prior. So prior. So I started out my career with Baxter Healthcare.

2:21Unidentified speaker (speaker_3): Okay.

2:21Unidentified speaker (speaker_2): Um and Baxter had a incredible education assistance opportunity. So they actually supported me. I went back and did my PhD when I was in um working for them. And quite frankly, as a chemist, one of the reasons I wanted to go real quick is I decided to study electrochemistry. Okay. So my PhD working in diagnostics happens to be in electrochemistry. Well, when you put the two of those together, you measure glucose.

2:47Unidentified speaker (speaker_3): Yeah.

2:47Unidentified speaker (speaker_2): Right. So that got me recruited into a company called Theracens. Theracense. I was the vice president of R and D at that point, doing the electrochemical strips and meters. Um, but we also had the first generation CGM called Navigator. And then Theresacent got acquired by Abbott. So I worked for for Abbott up until 2010. And then the board recruited me in to take a look at the technology of continuous glucose monitoring in uh in Cincinnatiana. So that's uh that's been the career.

3:15Unidentified speaker (speaker_3): Yeah. And so that's the interesting thing, is the electrochemistry side of it, because you know, my I don't have that chemistry background. So learning these CGMs over the years and understanding that it's that electrical reaction when you you know you put the sensor into the body and the glucose oxidizes with the sensor, it's quite fascinating. I mean, I I'd love to hear your thoughts on just how that technology has evolved within the CGM market.

3:39Unidentified speaker (speaker_2): Yeah, well it's been it's been pretty um, you know, incredible. And the technologies of those electrochemical sensors are are now pretty consistent. They started out in the striping meters, and just as you said, it's uh what's called an oxetoreductase. So it's an enzyme, it chews up glucose and it gives off electrons. So they all measure current, right? Whether you're doing and these are, you know, now for the last thirty years or so. Early, early on, you measured color that was generated in urine. Then they move to the blood drops with all these um current development. Well, they leveraged all of that. If you look at the the existing CGMs that are out there today, they're all electrochemical. So it's same thing. They have a mobilized enzyme, chew up the glucose, and they all measure current. Since the onic onics is a little bit different because it's in the body for an entire year. you can't really use an enzyme protein because they're not intended to be around that long. So that's one of the things that we had to we had to develop is a stable way to to measure glucose that wasn't enzymatic.

4:39Unidentified speaker (speaker_3): Okay, interesting. So yeah, why don't we kind of jump into the the ever since design? Um, because similar to the electrochemistry history behind CGMs, there's the the development of the implantable CGM has been around for a while as well, maybe not as long as 30 years, but pretty close. So what is the design features of the implantable itself? And just kind of for listeners who are new to the space, I mean, because my understanding is it's about the size of a rice kernel, maybe a little bit bigger than that, but can you know just uh uh w just talk through the design. features.

5:15Unidentified speaker (UNKNOWN): So it

5:15Unidentified speaker (speaker_2): it's a tiny pellet, you're right. It's about the dimensions are about four millimeters by fifteen. So m just a little bit shorter than the diameter of a penny, but but much, much thinner. Uh and it needs to be that size, of course, because you want to be able to do an insertion in the doctor's office as opposed to going into some surgical suite. So size really matters and that's a lot of what the design has gone into it. But EverSense was all built on the concept of being able to do that miniaturization, but you needed to get out to a year. Right. If you're gonna go ahead and put a sensor in, you want to get a lot of value out of it. So a year has always been the the design goal for it. And doing the stabilization of the chemistry and then protecting it because the body doesn't want something foreign that's in there. Right. Right. It's going to try to fight it off. So we've had to do a lot lot to stabilize it and make it viable for that 365 days. But that's the entire content. Um and the reason of course that you that you do that is because you want to, you know, you want to make it easier for a person with diabetes. The unfortunate reality, whether it's type one or type two diabetes, once you get diagnosed, you're going gonna to think about it for the rest of your life. Yeah. So those of us in the manufacturing world, the innovation, we know that if you can make it a little bit easier, right, and you do it in a quality way, people are

6:35going to enjoy your product and they're gonna reward you with a purchase. So we've been focusing on doing exactly that. We're all about duration. Yeah.

6:43Unidentified speaker (speaker_3): And let's talk about what is the technology exactly for measuring it within the body? Because you talked about how you can't use pre the same enzymes as you do with a 15-day CGM.

6:54Unidentified speaker (speaker_2): Right.

6:55Unidentified speaker (speaker_3): So what was the work needed to be done to understand what needed to be changed from that kind of traditional enzyme technology?

7:03Unidentified speaker (speaker_2): Yeah. So we use uh a fluorescent molecule that actually binds glucose, and it's been been around for a long time. Actually, it was done in some of the Nobel Prize work on it. It's based on a molecule called anthracine. anthane. Think of it as a big light bulb, right? It gives off a lot of light when it's stimulated. The problem for many years and why it didn't get implemented is because it's it wasn't water soluble. So what we figured out how to do, and is the basis of many of our early patents, is it actually goes into hydrogels. So what's on the surface of our sensor is a contact lens. Okay. And then inside of it is this light bulb that happens to bind to glucose. So depending on how much binding changes the amount of fluorescence that's given off, right, when it generates light. So we just measure light, which is directly proportional to the amount of glucose that's there.

7:50Unidentified speaker (speaker_3): Okay, interesting. Yeah. Never thought about the like wrapping it up with a a contact lens, especially for a contact lens where like myself. Yeah.

7:56Unidentified speaker (speaker_2): You need to be able to get light

7:57Unidentified speaker (UNKNOWN): through

7:57Unidentified speaker (speaker_3): it and

7:58Unidentified speaker (speaker_2): it needs to be biocompatible. That's

8:00Unidentified speaker (UNKNOWN): a

8:00Unidentified speaker (speaker_2): contact lens, right?

8:01Unidentified speaker (speaker_3): Yeah, exactly. And then the other thing. you talked about is you wanted to make sure it stretched out to three hundred and sixty five days. And I know, you know, several years ago it was a

8:10Unidentified speaker (UNKNOWN): ninety

8:11Unidentified speaker (speaker_3): day

8:11Unidentified speaker (speaker_2): sensor, then you made it into a hundred eighty day sensor and you made

8:14Unidentified speaker (speaker_3): it a

8:14Unidentified speaker (speaker_2): now the three hundred sixty five day sensor.

8:17Unidentified speaker (speaker_3): What what were the the str what was the strategy

8:20Unidentified speaker (speaker_2): and what

8:20Unidentified speaker (speaker_3): were the steps

8:21Unidentified speaker (UNKNOWN): needed

8:22Unidentified speaker (speaker_3): to be able to extend that life now four times from that

8:24Unidentified speaker (speaker_2): original ninety 90

8:25Unidentified speaker (speaker_3): days?

8:26Unidentified speaker (speaker_2): Yeah. So that really has been the basis of the RD. And uh, you know, there's hundreds of millions of dollars that have gone into the RD of the ever since product. The fundamental issue that we had to improve on has to do with that foreign body response. So something goes in, the body recognizes it, it will start to use the immune response to reject it. And what happens in all cases is you get a reactive oxygen speed. species that's generated. Macrophages and neutrophils come to the area, they recognize a form body and they give out these reactive chemicals. So us stabilizing it, so those reactive oxygen species, those ROSs didn't break it down, was really the technology development between 90 to 180 and 180 to 365. And as you can imagine, with an implantable product, it's not as if we can get the middle of the bell curve out to three hundred and sixty-five. We have to get all of the sensors out to three hundred and sixty-five. Right. Because you can't have a short term uh short sensor if you're gonna go through the process of planting it. So

9:28Unidentified speaker (speaker_3): if you want that durability, you want to make sure that 'cause

9:30Unidentified speaker (UNKNOWN): you

9:30Unidentified speaker (speaker_3): you have to ex-plant it essentially. You don't want to be the X plant early.

9:33Unidentified speaker (speaker_2): Exactly.

9:33Unidentified speaker (UNKNOWN): Yeah.

9:33Unidentified speaker (speaker_2): Exactly.

9:34Unidentified speaker (speaker_3): And so I mean, you talked about millions of dollars going into that R and D. I mean what were some of the breakthrough aha moments and what were some of those like hair grabbing type moments that you're like, okay, we gotta figure out another step to do that. 'Cause that's kinda the like I said, that seems like to be your biggest path over the last twelve years has been doing that extension.

9:55Unidentified speaker (speaker_2): It's actually been a lot of those little aha moments. There's never really one big one, but there's a lot that's gone into it. We have something like a hundred 120 issued US patents, right? So along the way, as a technology company, we've been putting out a lot of those elements. But it does go back to that uh that production, that stabilization in their in the reactive oxygen species. So, you know, one of the things that we did is we recognized, okay, how do you damp that down? Well, we stole from the cardiac pacing leads, right? So you put a pacing lead in the heart. Well, what's right next to the cardiac tissue is just a there's tiny tiny. steroid ring that works for 10 years delivering a small amount of dexamethasone.

10:32Unidentified speaker (speaker_3): Okay.

10:33Unidentified speaker (speaker_2): So we recognize, hey, let's not reinvent it, but let's go ahead and use that. So in our sensor, there's a tiny ring that would actually deliver dexamethasone for 10 years. Now, of course, we don't use it that long, but that's one of the things that you do to moderate the cellular response in the area.

10:48Unidentified speaker (speaker_3): Yeah, because I mean the those pacemakers, the the replacements. replacement cycle is about seven years. And so

10:53Unidentified speaker (speaker_2): exactly right. So you don't want an inflammatory response, right? Because that builds up insulation to the lead. So we said, let's go, let's go uh build on the shoulders of those that went before us and biostability.

11:03Unidentified speaker (speaker_3): That must have been pretty cool. Like someone the the person who mentioned that and you're like, Oh yeah, uh huh. Because I'm just thinking like that's how I'm thinking of it right now.

11:09Unidentified speaker (speaker_2): And that's that's exactly what product development is, right? Yes, of course you want to do the innovation, you want to do the RD, you want to do the differentiation. But it needs to be shrink wrapped in a box, sitting somewhere so somebody can use it. Yeah. Right. That the innovation has to be directed towards that.

11:25Unidentified speaker (speaker_3): Yeah. And then so you know, the other thing too, you talked about the durability of the product itself, but you need to make sure that the accuracy is consistent throughout. Um what has the real-world real world data showed um when you stretch it out to that 365

11:41Unidentified speaker (speaker_2): days? It's been an absolute focus. Um, and for those that you know that have been around for a long time, there have been a lot of technologies, especially in the non-invasive. There's always

11:50Unidentified speaker (UNKNOWN): been

11:50Unidentified speaker (speaker_2): the talk of can you do non-invasive glucose? The problem always is that when you try to look at a carbohydrate through the skin or with you know light that goes through the skin,

12:00Unidentified speaker (UNKNOWN): that

12:01Unidentified speaker (speaker_2): carbohydrate glucose looks like everything. every other carbohydrate on the surface of your cell. It's very, very hard to do. So there have been a lot of failures that have gone before it. So we recognize that if you're going to be a serious medical device, it has to work and it has to work very well. So our M A R D, if you heard that term, that's the average error, is eight percent. Um very, very competitive. A strip and meter is about five 5 and six 6%. percent. So it's within that domain, and that's allowed us, much like the other two that are out there, we have what's called that ICGM designation,

12:31Unidentified speaker (UNKNOWN): which

12:32Unidentified speaker (speaker_2): is the higher accuracy standard the FDA has put out, so that you can have interoperability with the pump. So it's very accurate. We're very proud. We have the best in class accuracy, especially at the low end for predicting hypoglycemia, which is uh which is really important because of that light generation.

12:49Unidentified speaker (UNKNOWN): Um

12:49Unidentified speaker (speaker_2): so we're excited about it. And importantly, that accuracy has to be maintained on day 364. The FDA makes us prove that extensively in our testing.

12:58Unidentified speaker (speaker_3): Yeah. And now is that you I heard you mention the the low it's good with the low predicting low volume, like low hypo moments. And that, as you say, that's so important for these patients because they if they do too much insulin, it's that's very um adverse advance events for them. What what makes the the light technology allow it to potentially be more accurate in detecting those low uh hypo moments?

13:21Unidentified speaker (speaker_2): So um think about the other technologies when there are low glucose it's just very, very tiny amount of current that needs to be generated. Okay. It's a pretty bright light bulb. Think of it that way. Right. When you walk into a room, of course it's going to be easier to see the brighter and bright it is. So we have the ability to to turn that up at low levels of glucose and not saturate it. So you can still tell high levels of glucose. Oh,

13:44Unidentified speaker (speaker_3): right.

13:44Unidentified speaker (UNKNOWN): It

13:44Unidentified speaker (speaker_2): has to do with a dynamic range capable.

13:46Unidentified speaker (speaker_3): Yeah, like I said, with the enzymes, if it's a low sugar, the less reaction, less reaction, less like electrical.

13:51Unidentified speaker (UNKNOWN): Oh yeah.

13:52Unidentified speaker (speaker_2): And therefore more air can propagate through. And sometimes you get a higher MARD or

13:57Unidentified speaker (speaker_3): at

13:57Unidentified speaker (speaker_2): the lower levels of glucose.

13:59Unidentified speaker (speaker_3): Yeah. No, it's it's actually interesting to hear about. The other thing that you just mentioned. is that it's uh an ICGM like Abbott, like DEXCOM. Which pumps are you currently integrated with? And what's what's the pathway to kind of expand that integration process? Because that is a big component for especially the patients who are on insulin, especially those type two patients on insulin, that's you're starting to see that more of an adoption of that but to combined combine scent. set.

14:24Unidentified speaker (speaker_2): Pumping, uh pumping is certainly starting to expand in type two. but of course it's really much more penetrated in type one. Right. And we're you know we are excited to participate in. So we have been selling an integrated system um with SQL MedTech for uh about the last year. And quite frankly, we've been very excited. It significantly beat the plans that we had for the number of patients that we're gonna that we're gonna choose ever since to partner with um with the twist pump. Uh and then do just next week we're actually launching with beta bionics

14:53Unidentified speaker (speaker_3): okay

14:53Unidentified speaker (speaker_2): so that'll be our second pump we're excited about working with that team they've got a great um you know a great current product with the eyelet they have a new generation coming out of patch pump in um in the spring that we're gonna participate with as well and then beyond that we will partner with the uh with the other guys that are coming it takes a little bit more development time and under unfortunately for us, that development time is done on the pump side, right? So we don't get to control it. But they're very interested. You know, I'm sure we'll talk about the freedom product, which is our super uh super exciting future that's coming. Um, they all very, very much want to be associated with that. So expecting in the next year or so we'll be bringing those next guys over. Oh,

15:34Unidentified speaker (speaker_3): yeah. No, we'll definitely be talking about freedom in a few minutes. I'm curious about the pumps because the you know there's two one you talked about with beta bionics and you know their mint um on the body wear is coming coming out next year. With them, how much time is needed to be able to get that integrated? Because one, you have the algorithm already. This the algorithm is the same.

15:56Unidentified speaker (speaker_2): Right.

15:57Unidentified speaker (speaker_3): Um so it uh it will read your data um from the CGM and it will make it its insulin dosing decisions based off of that data. So that should be pretty integrated, array, but the form factor is a little bit different. I know there's Bluetooth technology or other communication that needs to be involved. So when you look at that next product for beta bionics versus kind of another Other company that is doing it from scratch, is there less lead time needed to get to that new product? versus what um it's like you're doing it with a whole new company?

16:30Unidentified speaker (speaker_2): Generally that's very correct, right? When you do a derivative product. So my expectation is and and I don't know for sure, but obviously when they developed ILET, they used a communication protocol, it looks like XYZ. When they develop the Mint, it's pretty likely that they've leveraged that because, you know, that's the way they've done the development and they're gonna want to be able to talk to their next C CGM Gm that way. So very typically a follow on product would be much quicker than you know the uh the brand new stage.

16:57Unidentified speaker (speaker_3): Yeah. Okay,

16:58Unidentified speaker (speaker_2): interesting.

16:59Unidentified speaker (speaker_3): And so, you know, we'll we'll get to freedom next, but I think there's a product in between called Gemini,

17:03Unidentified speaker (UNKNOWN): am I correct?

17:04Unidentified speaker (speaker_2): Right.

17:04Unidentified speaker (UNKNOWN): Uh

17:04Unidentified speaker (speaker_3): so what are the key developments with Gemini over EverSence? And then, you know, what what what are the next steps with it rather?

17:14Unidentified speaker (speaker_2): rather a clinical

17:16Unidentified speaker (speaker_3): trial, um more product development, anything like that?

17:20Unidentified speaker (speaker_2): Yeah. So let's start with with EverSense 365. We talked about the sensor. We typically put it in the back of the arm. It does that that fluorescence, that light generation. Today, with uh with the EverSense 365, there's an external component. We of course call it the transmitter as well,

17:37Unidentified speaker (UNKNOWN): but there's

17:38Unidentified speaker (speaker_2): no through scale. skin component for ours because it's it's a full implant. But what that external component does is two things. It powers the sensor with near field technology. So it's like your Apple Pay, right? You put them in close proximity, it sends radio frequency back and forth and generates the power. And then number two, it Bluetooth talks to your phone or talks to your pump. Right. So those are the two pieces that we are incorporating. in the next generation. Generations. Gemini includes the battery. So we have an implant grade battery, just like you did in a pacemaker or a neurostimulation device that's been customized. So it's tiny and it matches up with our sensor. It will now do all the internal powering. That's Gemini. Okay. Right. So where would that be a great product? That would be for the much lower intensity testers. Think about if these, you know, somebody that's on basal insulin that isn't testing, isn't testing at night, let's say.

18:37Unidentified speaker (speaker_3): Yeah.

18:37Unidentified speaker (speaker_2): You you want an in-frequency. So that sensor will be generating its own power, 24-7, and you can wand it with your phone and use the NFC in your phone to extract the last eight hours.

18:48Unidentified speaker (speaker_3): Interesting. Okay.

18:49Unidentified speaker (speaker_2): So if you're uh let's say you're a diabetic that isn't on insulin yet, right? You're not that frequent testing, you just want to do it at your convenience, you can have that sensor for an entire year that you just wand and say, okay, what's it what's it look like overnight? That's really what Gemini is intended to be.

19:04Unidentified speaker (speaker_3): Okay. Interesting. And you know that at least it's starting the getting the power generation internally done.

19:10Unidentified speaker (speaker_2): It's the risk risking of the product and doing that internal plantable planable battery. Yeah.

19:13Unidentified speaker (UNKNOWN): Now

19:14Unidentified speaker (speaker_3): is there is there a Gemini study because it it seems like the algorithm is the same. It's just the power generation.

19:23Unidentified speaker (speaker_2): So

19:23Unidentified speaker (speaker_3): is there a Gemini study

19:24Unidentified speaker (UNKNOWN): that's needed?

19:25Unidentified speaker (speaker_2): There is. Okay. The FDA is going to want you to show okay, what's different between this product and the last. And as you know, one of the nice things the FDA has given us with the ICGM is that you're down regulated from a class three to a class two. So class two means it's a five ten K and you have to show equivalency. So the clinical trial will be Gemini and that and then the clinical trial is going on right now. So Gemini will be in one arm, the EverSense 365 will be in the other arm, and the agency asks us to show that the power generation from the implanted battery results in the same glucose that you get on the other arm. that comes from that transcutaneous near field powering.

20:05Unidentified speaker (speaker_3): And is a lot of that confirmation. I feel

20:08Unidentified speaker (UNKNOWN): like

20:09Unidentified speaker (speaker_3): because you're having an internal battery, a lot of the confirmation you need to do with the Gemini study is to make sure that that second half um accuracy is the same as the second half accuracy as we talked about with the EverSense Ever since 365 and showing consistency throughout the

20:23Unidentified speaker (speaker_2): entire 3065 days, right? It is it true, but we actually feel pretty good about it because the sensing part of it, that chemistry, is exactly the same. So it is ever since 365. We've just appended the battery to it. So they're really going to focus on that powering part of it, right? Which actually allows us to do the the clinical trial a little bit faster. Interesting. Okay.

20:43Unidentified speaker (UNKNOWN): Um

20:43Unidentified speaker (speaker_3): and now yeah, now you got the Gemini, but it's so not that sounds like it's a stepping stone for the freedom product.

20:50Unidentified speaker (speaker_2): Right.

20:51Unidentified speaker (speaker_3): So between Ever Since 365 and Gemini, what is the Freedom product?

20:56Unidentified speaker (speaker_2): So

20:56Unidentified speaker (UNKNOWN): so we

20:56Unidentified speaker (speaker_2): talked about those two technology steps, right? The first one we is the battery. So Gemini will have the battery. Freedom has the battery plus the Bluetooth.

21:05Unidentified speaker (speaker_3): Okay.

21:06Unidentified speaker (speaker_2): Right. So then you've completely eliminated that transmitter. Right. And that's really intended for a the high high-intensity intensity classic user that's using any of the uh of the CGMs today that are integrated with the pump. Right. So that will implant a Bluetooth chipset and a Bluetooth antenna. We take out the near field antenna so that for that swiping and put in the Bluetooth. So that's the development work that's going on. We announced just a couple of weeks ago that we're doing our first inhuman testing. On uh we have the authorization to do that. for freedom. And the intention of that first inhuman, it's not the pivotal trial yet for product approval, but it is the inhuman experience to how well is that Bluetooth working, right? Constantly get a glucose result every five minutes when you need it. So we're excited to be there or watching we're watching those patients real close.

21:57Unidentified speaker (speaker_3): Yeah, and actually I'm just curious about the engineering side because you know, I'm thinking about my iPhone. and you know, it's been the same form factor for several decades, and then kind of squeeze more and more features, bigger chips, more higher power battery. With the EverSense and the Gemini and the Freedom, it's so tiny.

22:17Unidentified speaker (speaker_2): Right.

22:18Unidentified speaker (speaker_3): What what were the engineering feats that you needed to do to be able to add a power source and the Bluetooth capabilities into that small format? form

22:26Unidentified speaker (UNKNOWN): factor.

22:27Unidentified speaker (speaker_2): That's exactly the engineering challenging. As I said, going you know right back to the early comments, it has to be small enough that you can insert it in a doctor's office.

22:36Unidentified speaker (UNKNOWN): Yeah.

22:36Unidentified speaker (speaker_2): Right. If you had to go into a, you know, into an operating room to put it in, nobody's going to choose that product. Right. So it's got to be tiny. Um, and all of our engineering investment is in that miniaturization. One of the big advancements happened a couple of generations. ago. You remember Bluetooth L E, well Bluetooth low energy. Yeah. Right. That was important that we had access to that.

22:58Unidentified speaker (UNKNOWN): Uh,

22:58Unidentified speaker (speaker_2): of course, because you don't, you know, in the old days, you know, DEXCOM very, very early on did a great job at exploring a long term implant using that electrochemical approach. Yeah. But they had to have a battery that was about the size of a double A battery. Yeah. Right. And that's just way too too large to actually use. So we've gone down to this tiny cylinder again. It's about four millimeters by about twelve. It's appended on the end of it. So

23:23Unidentified speaker (speaker_3): it kind of sounds like I've had previous guests on and they've had the design in mind and they were just waiting for the right technology to come about. And it sounds like that's the case here where you probably had that understanding, okay, we need this smaller factor or we need that. lower energy to be able to do the same Bluetooth capabilities, but without burning through our power source. Um, it just sounded like you guys are ready for that technology to come out and then you were ready to

23:50Unidentified speaker (UNKNOWN): pounce.

23:51Unidentified speaker (speaker_2): Certainly you knew the need was there, but what's what always happens, right? Technology evolves. Yeah.

23:56Unidentified speaker (speaker_3): As

23:56Unidentified speaker (speaker_2): they said, you stand And on the shoulders of those that went before you, right? And that's why you're always making an investment to come out with new generations, whether it's you know, G7 or Libre III or ever since on 365, you're constantly doing an update because that's what people need and expect, right?

24:13Unidentified speaker (speaker_3): Yeah.

24:14Unidentified speaker (UNKNOWN): And

24:14Unidentified speaker (speaker_3): so you talked about the first inhuman study um for freedom. Is there any timeline long-term Long term when you would like to get this product out into the market or clinical trial? trials, anything like that?

24:28Unidentified speaker (speaker_2): Yeah, so we're forecasting using this data, continue to do the optimization of that that Bluetooth, the circuitry, as well as the software control of it. Um, and we'd very much like in 2027 to be able to do our pivotal trial where we evaluate that additional powering that we talked about and the Bluetooth in its pivotal trial.

24:49Unidentified speaker (UNKNOWN): If

24:49Unidentified speaker (speaker_2): we're successful with that. it's encouraging where we're headed right now. That would allow us to to do that pivotal trial in twenty twenty seven, submit for a five ten K in in twenty twenty eight, and then improve it um in the middle of the year, let's say of twenty twenty eight. So we're looking about eighteen months uh from now is our is our target.

25:11Unidentified speaker (speaker_3): Yeah. Okay. Let's go back then to the market itself. We talked about the type ones, we talked about the type twos, we talked about the type twos that are just using basal insulin. We talked about how pump penetration is higher in the type one, although it's still kind of in that forty to fifty percent range. It's kind of a a slight s you know a slight slope, but it's mostly plateauing over the past five, ten 10 years. A lot of adoption is starting in the type two space. What is your view of that market overall? What are some of your takes that maybe I'm not seeing? Um, and kind of where where do you see the opportunities come from that?

25:51Unidentified speaker (UNKNOWN): Well,

25:51Unidentified speaker (speaker_2): there's a lot of utilization growing over the years, obviously. Um, you know, I think we'll be about $15 billion dollars worldwide in CGM. So it's become a major medical device for people with diabetes. and it's brought a lot of clinical value as a result of that. It is going to continue to grow. You're likely aware that there are conversations going on right now to get CMS to add coverage for non-insulin people with diabetes to use CGM. That absolutely makes sense from a clinical value perspective. Remember the damage that happens from diabetes is that long-term exposure to elevated hyperglycemia. Type two without insulin typically doesn't have hypoglycemia, but that long-term consequence is what hurts your eyes or what hurts your kidneys, right? It was causes, you know, the the leg amputations, right? So they have every need as well to frequently continuously be monitoring glucose. Yeah. So I think that is going to be a big expansion. Um,

26:51of course, we have to worry about the economics. So I think some of this competitive bidding that you may have heard about, right? So you can manage the control. I think you're going to see that paired up with the expansion of the label with the competitive bidding so that, you know, as a society, we can afford to appropriately treat all the people with diabetes. But it's it it's going to continue to grow for CGM. The clinical benefit is just clear.

27:13Unidentified speaker (speaker_3): Yeah. Yeah. And I think the other thing too is we're seeing with the pairing with the insulin pump. And it sounds like your comments with your SQL partnership has been better than expected. So do you see the opportunity more in patients who are already on a pump or already maybe manually injecting um insulin right now, waiting for that right pump and CGM opportunity? I

27:37Unidentified speaker (speaker_2): I I think patient choices. choice is is critically important and you are seeing some of that happen. Um today, honestly, we're seeing about 90% of our patients are actually coming from an existing CGM. So they're choosing the long-term implant because they like the duration and and some of the attributes associated. About 10% are brand new, so they've all been aware now, right? But they were looking for something different. Um and you know, in our case, the the long-term implant were worked out well for them. So patient choice is is absolutely important. You see the same thing with pumps. Some people like the traditional durables, some people don't like a long infusion set, right? So you get to more people by offering more choice.

28:16Unidentified speaker (UNKNOWN): Yeah.

28:16Unidentified speaker (speaker_3): And so I guess then because there has been an inflection with the company, with the financial results over the past few quarters. Is that just then more people are becoming aware that this product is a one? once a year product and you just I don't want to say set and forget it, but you implant it and then you don't have to worry two weeks later about having another one ready to go um to be able, you know, just that level of let's call it or l you know, lower maintenance level for the actual product itself. Is that something that these patients are catching on to and

28:47Unidentified speaker (UNKNOWN): being

28:48Unidentified speaker (speaker_3): more aware about?

28:49Unidentified speaker (speaker_2): It's it's absolutely gets down to awareness. right? We we've had the product approved now for two years. So we've been able to talk about it. It's taken some time to get the word out there, but now you're absolutely seeing, right? The word of mouth is there, the social media advertising.

29:04Unidentified speaker (UNKNOWN): So

29:05Unidentified speaker (speaker_2): it starts with the product. We're able to invest now the the DTC. We do a lot of meta advertising, right? Um we use the social media. influencers to to make their participation in recommendations because that's important for people with diabetes. And we're just starting to get more and more people aware of it. And it's uh it is growing. We are in an exciting time.

29:26Unidentified speaker (UNKNOWN): Yeah,

29:26Unidentified speaker (speaker_3): that's interesting. So you're kind of almost seeing the DTC and go into just the regular healthcare providers. Those commercial strategies kind of complementing each other then, right?

29:37Unidentified speaker (speaker_2): Yeah, they absolutely do. What in fact what happens a lot of times is even though a lead may come in in DTC, um, it may have been stimulated that way. Somebody sauner it, and then what do they do? They go home and they'll they'll Google it, they'll learn more about it, and then they go to their doctor. Yeah. And then they'll ask forever since and then it becomes actually a sale that will come in through the what we call the HCP or the healthcare professional channel.

29:58Unidentified speaker (speaker_3): Yeah.

29:59Unidentified speaker (speaker_2): Right. So there's a lot of overlap between the two. Yeah,

30:02Unidentified speaker (speaker_3): because that's the other thing too. Is you you have to make sure that the doctors are aware of the products as well. They may not be on those TikTok videos the same way as

30:08Unidentified speaker (UNKNOWN): other

30:08Unidentified speaker (speaker_3): the customers are. Um so what's I mean, is it just that also just getting your sales force out there and just banging the drum about, hey, this is what we have with this technology. It's a year long. Um, just so the doctors are aware too. And so when they are both the customer and the doctor are aware, you kind of create that right. combination.

30:28Unidentified speaker (speaker_2): You do, although obviously there's a lot of considerations. So many people that treat the type 1 diabetes tend to be diabetologists or endocrinologists, right?

30:36Unidentified speaker (UNKNOWN): So

30:36Unidentified speaker (speaker_2): we have a sales force that's calling just on those large treating clinics, right? So it that's about education of the doctor and the nurses. So they'll make a recommendation or a suggestion forever for EverSense sense as an alternative. The other side is the DTC, and that's more from the customer pull. pool. So they're the ones that are aware of it and they'll come in and ask about it. Or as I said, 90% are actually switching. So they're very, very familiar with CGM, right? So they're just saying, hey, it's something about EverSense I like. I want to go get that one, Doc. So I'd like you to write a script for it.

31:05Unidentified speaker (UNKNOWN): So

31:06Unidentified speaker (speaker_2): it's really two different channels depending on where the push is coming from. Yeah. Patient or down from the top.

31:12Unidentified speaker (speaker_3): And it gives you the access, the ability to take advantage of. both opportunities.

31:16Unidentified speaker (UNKNOWN): Right.

31:16Unidentified speaker (speaker_3): Um I was just curiosity, who is actually the one the is it the doctor that's actually implanting it? So they need to be trained to implant and explant the the sensor?

31:26Unidentified speaker (speaker_2): So about sixty percent of our insertions are being done by some type of doctor, medical professional.

31:32Unidentified speaker (UNKNOWN): A lot of

31:33Unidentified speaker (speaker_2): times it's the large diabetology clinic. Some of our biggest accounts, as you can imagine, is they're they're doing quite a bit. So, you know, more type ones that I said will go to see that. Forty percent now of our insertions are actually being done by a group that we've set up. We call it Eon Care. And what Eon Care is, is the network of nurses that contract with us through 1099. So they're not employees, but they have a relationship. And the reason that we did that is because the growth that we've seen in type two diabetes, they're not treated by those diapetology clinics, right? They're typically treated by primary care.

32:09Unidentified speaker (speaker_3): Yeah.

32:10Unidentified speaker (UNKNOWN): But

32:10Unidentified speaker (speaker_2): there aren't going to be as many of them. So those primary care doctors are probably not going to spend the time to get certified on doing insertion. So what we do is we'll pair those up, right? So today we've got about a hundred nurses in our network. We're going to try to expand that to about 120 by the end of the year. So it grows pretty fast. So these are all nurses. Uh they tend to be in mid-spas or aesthetic clinics, right? That are doing procedures. Right. Um, the other big difference for the implantable is we have CPT codes to do the insertions and the removals. So those those nurses typically were and we have the nurse indication, will we'll actually do the procedure and then they'll bill against those CPT CPZ codes. If it's a Medicare patient, right? They'll build to do that that insertion. So it's an economic that they participate in.

32:57Unidentified speaker (speaker_3): Yeah. And I and I'd love to circle back to that. You talked about the type two going to those Eon programs. Um, because it kind of goes back to, you know, it sounded like, or if I connect the dots with your other comments about the 90% of the patients are writing on CGMs, it sounds like these are the more serious types. type two patients, either they're on the basal bolus insulin or

33:19Unidentified speaker (UNKNOWN): just

33:19Unidentified speaker (speaker_3): basal insulin. Um, is that the right thought to take, or is there more opportunities that you're seeing in the type two space, especially for those are not on insulin at this moment?

33:29Unidentified speaker (speaker_2): So most of the early adopters, you're right, are the ones that have the greater need to do more frequent testing because they're taking more insulin. So it tends to be the MDI, the multiple daily injection patients. Um, we are growing now with the pump connectivity as well in the predominantly the type one space. I think the future is going to be very strong with a with a facile approach in the people that are not yet on insulin. But today, almost all of our patients, as you can imagine, are on insulin because that's where the reimbursement is.

33:59Unidentified speaker (speaker_3): Yeah. Is that and then so I guess then we can just talk about that strategy. I guess. Is there is there sh a p I guess that just goes along with what Dexcom is doing with their push for the CMS um uh reimbursement for those patients. Is that something that because you're as well as an IC GM, you'll just be able to benefit from that as well when it comes out?

34:19Unidentified speaker (speaker_2): Certainly the clinical studies that have been done. DEXCOM's NextCom's been a big sponsor of those. There have been others as well have continued to generate that clinical confirmation that they got, you know, they can use to get comfortable with doing the reimbursement. So yes, the implantable product will be part of that. We'll work with CMS to make sure that they fully understand, and they do, that this is another CGM alternative. Um they've actually been great partners. We've worked with them for years to first get the reimbursement, the CPD codes for the 90-day ninety-day product, then

34:49Unidentified speaker (UNKNOWN): the

34:49Unidentified speaker (speaker_2): 180 one eighty and the 370. three sixty-five. So they've been active participants in the innovation development for us as well.

34:55Unidentified speaker (speaker_3): Yeah. So yeah, it sounds like there's a lot of tailwinds for you with the the product development, the reimbursement, this the product awareness. I mean, I guess then you have to put on as a CEO your kind of your financial hat and you have to talk up think about investing in manufacturing. I mean, 'cause Cause I mean this is this feels a more complicated design because it's once a year versus kind of the mass produced CGMs that you have with m Dexcom and Abbott. So what what's the what's the steps needed to be able to expand that manufacturing capacity?

35:29Unidentified speaker (speaker_2): Yeah. Uh and obviously that's something that we look at a lot 'cause we're producing in the tens of thousands.

35:34Unidentified speaker (speaker_3): Yeah. But

35:34Unidentified speaker (speaker_2): we want to be up there with the big guys and we will that are producing in the millions, right? So scale is is absolutely something we focus on. Today what we do is kind of a three-part manufacture. Um the first is those microelectronics assemblies. Those are pretty scalable and pretty good. As you can imagine, there's a lot of electronics that are produced in high volume. You need to do it as a medical device um manufacturer. And we have partners um today, they're in the old eastern Germany, they're their old Silicon Valley that

36:01Unidentified speaker (UNKNOWN): they

36:01Unidentified speaker (speaker_2): do those electronics for us. Um we have a very strong partner that does that polymer chemistry on the surface. That's kind of step two. And then step three is we do terminal sterilization, of course, right? They all need to be they all need to be sterile. So those are the three steps that we focus on. Really step one and step three are pretty scalable. Available.

36:21Unidentified speaker (speaker_3): Yep.

36:21Unidentified speaker (speaker_2): Right? It's step two in the middle where we'll have to invest some automation, some robotics. right? Probably a dedicated facility in the future for us to go from ten thousands to hundred thousands and then hundred thousands to millions. We do have the advantage though, of course, that we produce one sensor per year.

36:39Unidentified speaker (speaker_3): Right.

36:39Unidentified speaker (speaker_2): Right. So when you produce that one sensor, you don't we don't have to produce twenty-four. Well

36:44Unidentified speaker (speaker_3): that's the thing. You only have to produce really two percent of the capacity that for for that index com comp has to do. Yeah.

36:50Unidentified speaker (speaker_2): And quite frankly, one of the things that we're s very, very proud of if you look at the financials, has to do with our our gross margins. Yeah. Right. And the gross margins, even at the small scale, are in the sixties already, which is pretty attractive for a medical device company.

37:04Unidentified speaker (speaker_3): Yeah.

37:04Unidentified speaker (speaker_2): But they're there

37:06Unidentified speaker (UNKNOWN): because

37:06Unidentified speaker (speaker_2): we do one consumable a year, right? So you amortize that cost to that sensor over three 365 hundred and sixty five days. Right. So that drives a lot of it for us.

37:13Unidentified speaker (speaker_3): And I'm just curious because you talk about talked the polymer and we talked about how it's you know similar to a contact lens because of the material and the you know being able to be clear. Is that something then that is feasible or relatively feasible because of the millions and millions of contact lenses that are produced per year by the Alcons and the Coopers of the world?

37:34Unidentified speaker (speaker_2): So it's a great, uh, a great point because actually the partner that we use company is called Contumac. They've been a great partner for they are one of the world's supplier of hydrogels to contact lenses and interocular lenses. Yeah, that's exactly right. Scaling up those polymers is what they do very well.

37:50Unidentified speaker (speaker_3): Yeah. Interesting. So that sounds like that's set. And you're already at your gross margins in the 60s. So as you kind of build the this scale, build this awareness, build the adoption rate for these patients, kind of how do you envision then reaching

38:05Unidentified speaker (UNKNOWN): a

38:06Unidentified speaker (speaker_3): level of break even, whether it's EBITDA or cash flow?

38:09Unidentified speaker (speaker_2): Yeah. Uh we're making great progress on that. Um right now we do have um the Freedom product coming in about the eighteen month time period. And when we get to that product, that's the break break-even even for us, right? Um the gross margin comes down because that transmitter goes away. Mm-hmm.

38:26Unidentified speaker (speaker_3): Okay.

38:27Unidentified speaker (speaker_2): But we also know that the scale is going to go way up on that product as well. So you're going to get economies of scale. So we're going to continue to make the investment. We have the money in-house to do that investment for the next 18 months, but we'll be breakeven in that uh in that time. Okay. And we feel very good about where we are today.

38:41Unidentified speaker (speaker_3): Interesting. And then let's just then, you know, take a step back and think about the big picture here. Yeah. And it's funny for me to say because we just talked about Gemini. We and talked about freedom. and the those developments and about a sensor that can be in your body for 365 days. But there's several things that I could think about over the next few years. First is then I'll just start with the first one is you know, we go from 90 days, we go from 180 days, we go to 365 days. Is this kind of what we're seeing with Moore's Law, where you can be able to double this technology and then for sensiotics? sensian's case, double the life of these products. Um, or is there at some point a ceiling that you can get with this type of technology?

39:23Unidentified speaker (speaker_2): Well, we're we're certainly going to continue to look at expanding. You know, that is very important as well. Now, however, you're you're signing up for not only expanding the life of the chemistry, but you're also expanding the life of the battery. Right. Right. Because those can't be broken apart anymore when we go to the freedom product. And we will be on a single platform with freedom when we get to it. So there is more innovation that's going to be required to get there. But as you know, I mean, just look at diabetes technology in the last two decades. Yeah. Right. It's it has just thankfully exploded for people with diabetes. So I feel very confident as a technologist will be there. I, of course, can't describe it because I don't know what it is yet, but you will move in that. direction and that innovation will come.

40:04Unidentified speaker (speaker_3): And it sounds like similar to how it is with um what we're some of the other technology that you were waiting for for freedom, you had the design in your head ready to go. You were just waiting for that small battery, you were waiting for that low energy Bluetooth. It just sounds it sounds like it's there. It sounds like you got a lot of good developments going on, and it's just now waiting for the rest of the technology to catch up with your ideas.

40:26Unidentified speaker (speaker_2): Go go. get it and you know go from R, right? The creation into D. There's a there's a you know a significant defined path that you need to do to develop. You need to do the verification, validation, the regulatory approvals, right? The manufacturing scale that you talked about. Yeah, that's all part of D so that you can bring it to people. But we are in the business of D, right?

40:46Unidentified speaker (UNKNOWN): Yeah. So

40:47Unidentified speaker (speaker_3): it's kind of the then no I'll kind of close out and then you know go through. we talked about your career and, you know, your your time from Sensionics from your day one to now has been a lot of product development and new technology out there that's really helping these patients. How do you go about using those lessons learned there to kind of go into the next chapter as we kind of expand this technology and we make it more accurate and we make the insulin dosing in the pump side more accurate for these patients overall.

41:17Unidentified speaker (speaker_2): Yeah. I mean that's an area that we haven't spent uh time on. But as you know, there's been a number of different developments in the algorithm as an example. Yeah. Right. I think what you're going to start to see is you're going to see some differences in performance be between the different algorithms, right? The partnership that we have with SQL, um, we've been able to show a 76% time and range, right? Just by putting somebody on EverSense and SQL, they'll go to a 76% time and range. That's incredibly exciting to be able to do that. And I think one of the big differences there is you've got the compliance of the EverSense that you're going to be on for 365. Yeah. And you've got a very you know expanded, very capable loop algorithm does a great job at uh you know of control of the insulin delivery. So y you know, you certainly take that historical perspective and, you know, advance it with each one of the generations. And as you see, as we all introduce those new generations, each one gets better, more expanded, more capable than the one before it.

42:17Unidentified speaker (speaker_3): Yeah. I'm I'm looking forward to seeing how these next generations help the patients

42:21Unidentified speaker (UNKNOWN): Yeah. further.

42:21Unidentified speaker (speaker_2): The next the next 10 years are going to be incredible. And and hopefully some of these um, you know, immune protection technologies, we don't need to be talking about type one anymore, right? Let's

42:31Unidentified speaker (UNKNOWN): hope

42:31Unidentified speaker (speaker_2): in the next decade that goes away.

42:32Unidentified speaker (speaker_3): Yeah. Well, hey Tim, thank you for joining us today.

42:35Unidentified speaker (speaker_2): Great. Thanks for having us.

42:36Unidentified speaker (speaker_3): Yeah, and uh thank you to our producers, Adidia Samani and Miriam Thauele for all the behind the scene work. And thank you to our listeners for tuning in today. We hope you join us for future episodes. And if you'd like to stay up to date, you can click the subscribe button on Spotify or your favorite streaming platform. Take care.

43:29Unidentified speaker (UNKNOWN): It is

43:38Unidentified speaker (speaker_0): Here are five reasons to subscribe to Bloomberg News Now. Number five, you get the latest news from around the world instantly. Number four, it saves you time. Your day's busy. Catching up takes just a few minutes. Three, it's available 24 hours a day whenever you need it. Two, it's convenient. Listen on your smartphone or smart speaker. And number one, it's easy to find. Subscribe on Apple Podcasts, Spotify, or anywhere. you listen. Five reasons, one simple way to stay on top of the news. Bloomberg News Now.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights